“Promising Effectiveness and Safety of Conversion Surgery for Initially Unresectable Hepatocellular Carcinoma Using Lenvatinib Plus TACE and PD-1 Inhibitor”

https://pubmed.ncbi.nlm.nih.gov/38114383

Conversion surgery for initially unresectable hepatocellular carcinoma using lenvatinib plus TACE and PD-1 inhibitor shows promising effectiveness and safety, with potential for reducing risk factors for postoperative recurrence.